<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04171583</url>
  </required_header>
  <id_info>
    <org_study_id>MZM study</org_study_id>
    <nct_id>NCT04171583</nct_id>
  </id_info>
  <brief_title>Mucoid Staphylococcus Aureus in Cystic Fibrosis Airways</brief_title>
  <acronym>mucostaph</acronym>
  <official_title>Characterisation of Mucoid Staphylococcus Aureus Recovered From the Airways of Cystic Fibrosis Patients: Prevalence and Impact on Clinical Course</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Muenster</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Muenster</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recently, the investigators described a new mucoid phenotype of Staphylococcus aureus
      cultured from the airways of cystic fibrosis (CF) patients.In this observational study, the
      investigators plan to determine the prevalence of mucoid S. aureus in respiratory specimens
      of CF patients and a possible impact of mucoid S. aureus on lung disease severity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      S. aureus is one of the first isolated pathogens recovered from the airways of CF patients.
      In many patients, S. aureus persists for decades in spite of antibiotic treatment and host
      defence. During persistence in the airways, S. aureus needs to adapt to this hostile niche.
      Just recently, the investigators described mucoid S. aureus isolates as a so far not reported
      phenotype recovered from the airways of CF patients. These mucoid isolates carried a
      5bp-deletion in a part of the &quot;intercellular adhesion operon (ica) leading to
      hyper-expression of biofilm. So far, neither the prevalence of mucoid S. aureus nor the
      impact on lung disease in CF patients is known. The investigators plan to perform a clinical
      study to determine the prevalence of mucoid S. aureus isolates in a cross-sectional study and
      the impact of identified mucoid S. aureus on the clinical course of the lung disease by
      observing patients with mucoid S. aureus for 12 months in comparison with a group of age-,
      gender- and P. aeruginosa-positive/negative matched group of S. aureus-positive patients
      without mucoid isolates.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2019</start_date>
  <completion_date type="Anticipated">May 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>lung function of patients with mucoid S. aureus will be compared to age and gender matched patients with only normal S. aureus</measure>
    <time_frame>one year</time_frame>
    <description>lung function assessed by FEV1% predicted, which is performed during the visits at the cystic fiboris center, will be reported in case report forms to the investigator</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">700</enrollment>
  <condition>Staphylococcus Aureus Pneumonia</condition>
  <condition>Lung Diseases</condition>
  <condition>Cystic Fibrosis</condition>
  <condition>Lung Function Decreased</condition>
  <arm_group>
    <arm_group_label>mucoid S. aureus</arm_group_label>
    <description>CF patients with mucoid S. aureus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non-mucoid S. aureus</arm_group_label>
    <description>CF patients with non-mucoid S. aureus</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      respiratory specimens: throat swabs, sputum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        CF patients with chronic S. aureus in respiratory specimens
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  CF patients with chronic S. aureus in respiratory specimens (50% positive S. aureus
             cultures within one or two years before recruitment)

        Exclusion Criteria:

          -  none
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barbara C Kahl, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Muenster</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Barbara C Kahl, MD</last_name>
    <phone>0049-251-83</phone>
    <phone_ext>55358</phone_ext>
    <email>kahl@uni-muenster.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Wien</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabine Renner, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Essen</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florian Stehling, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>LMU München</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susanne Nährig</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Muenster</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angelika Duebbers, MD</last_name>
      <phone>0049-251-83</phone>
      <phone_ext>47746</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clemenshospital</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Küster, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Rostock</name>
      <address>
        <city>Rostock</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manfred Ballmann, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Tübingen</name>
      <address>
        <city>Tübingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Uta Graepla-Mainka, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 15, 2019</study_first_submitted>
  <study_first_submitted_qc>November 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 21, 2019</study_first_posted>
  <last_update_submitted>November 19, 2019</last_update_submitted>
  <last_update_submitted_qc>November 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Muenster</investigator_affiliation>
    <investigator_full_name>Barbara Kahl</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>cystic fibrosis</keyword>
  <keyword>staphylococcus aureus</keyword>
  <keyword>mucoid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia, Staphylococcal</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

